Introduction
============

The presence of mutations in the kinase domain of epidermal growth factor receptor (*EGFR*) gene in non-small cell lung cancer (NSCLC) patients has been regarded as a predictive marker of good response to tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. Nearly 90% of these mutations occur as either multinucleotide in-frame deletions in exon 19 or as single missense mutations that result in substitution of arginine for leucine at position 858 (L858R) in exon 21. However, after a median of approximately 10 months from the onset of TKI treatment, some patients whose tumors were initially sensitive to EGFR-TKIs have eventually developed acquired resistance.[@b1-ott-7-513]--[@b3-ott-7-513]

Test of biopsied tumor after disease progression has shown that half of these TKI-resistant cases contained a second site mutation in the *EGFR* kinase domain.[@b4-ott-7-513]--[@b6-ott-7-513] The most common alteration involves a C-T (cytosine to thymine) change at nucleotide 2369 in exon 20, which results in substitution of methionine for threonine at position 790 (T790M). Cell lines with *EGFR* T790M mutation have been shown to have a proliferative advantage over wild type (WT) *EGFR* due to its increased kinase activity and downstream signaling.[@b7-ott-7-513] Mulloy et al[@b8-ott-7-513] showed the *EGFR* T790M/L858R double mutant exhibits a substantial increase in phosphorylation compared with the *EGFR* L858R mutant alone. Nevertheless, Oxnard et al[@b9-ott-7-513] and Arcila et al[@b10-ott-7-513] also observed lower growth rate in cell lines harboring both the *EGFR* exon 19 deletion and T790M mutation compared with cells harboring only the exon 19 deletion. Considering that the current in vitro results have been inconsistent, the impact of primary *EGFR* T790M mutation on the prognosis of NSCLC patients needs to be studied.

Bell et al[@b11-ott-7-513] reported a family with multiple cases of NSCLC associated with germline *EGFR* T790M mutation, where four of the six available samples from two patients showed an activating *EGFR* mutation (L858R, in-frame deletions in exon 19 or G719A). But in another series, *EGFR* T790M mutation was never found among 237 NSCLC family probands.[@b7-ott-7-513] Thus, the finding of an NSCLC patient with primary concomitant T790M mutation in the kinase domain of *EGFR* was rare event in the available series. Not much is known about this subset of cases. Here we report the clinicopathological characteristics and clinical outcome of NSCLC patients whose tumor harbored T790M along with an activating *EGFR* kinase domain mutation, with the aim of identifying the molecular profile of this subset of NSCLC patients.

Materials and methods
=====================

Patients and specimen collection
--------------------------------

We consecutively enrolled patients with newly diagnosed primary NSCLC between October 2007 and October 2012. All patients provided written informed consent and underwent radical surgery. Eligible patients for this study had to meet the following criteria: review of pathological diagnosis of NSCLC by morphological features and immunohistochemistry staining, confirmed by two pathologists (L Shen and Y Li); sufficient tumor tissue and corresponding normal tissue available for analysis; and patient had not received neoadjuvant treatment. This study was approved by the institutional review board of Shanghai Cancer Center, Fudan University, Shanghai, People's Republic of China.

Mutation analysis
-----------------

After the surgery, samples were divided into two parts: one part was fixed using formalin and embedded with paraffin to make pathological sections; the other part was snap-frozen in liquid nitrogen at the time of resection and stored in liquid nitrogen. Ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) were extracted from tumors and distant histological normal lung, after frozen specimens were dissected into TRIzol^®^ (Life Technologies Corp, Carslbad, CA, USA). Total RNA samples were reverse transcribed into complementary DNA (cDNA).

*EGFR* (exons 18 to 21), *KRAS (Kirsten rat sarcoma viral oncogene homolog)* (exons 2 to 3), *HER2 (human epidermal growth factor 2)* (exons 18 to 21), *BRAF (v-raf murine sarcoma viral oncogene homolog B)* (exons 11 to 15), *PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha)* (exon 9 and exon 20) were amplified by polymerase chain reaction (PCR) (Eppendorf Mastercycler^®^ nexus; Eppendorf, Hamburg, Germany) using complementary (c) DNA. For detection of *EML4 (echinoderm microtubule associated protein like 4)--ALK (anaplastic lymphoma receptor tyrosine kinase)* fusions (multiple 5′ primers, including *EML4 E2F, EML4 E13F, EML4 E18F* and fixed 3′ primer located to *ALK E20R*, were designed to amplify all known fusions variants, as previously described).[@b12-ott-7-513]

cDNA PCR products were assessed using the Sanger direct sequencing method[@b13-ott-7-513] in the forward and reverse directions. All mutations were verified by analysis of an independent PCR isolate. When combined *EGFR* mutations were found in the cDNA PCR product, separated genotyping of each exon was performed using DNA PCR product.

Fluorescence in situ hybridization
----------------------------------

Fluorescence in situ hybridization (FISH) testing (ThermoBrite StatSpin^®^; Abbott Molecular, Abbott Park, IL, USA) was performed on the corresponding formalin-fixed paraffin-embedded specimens matching the frozen specimens used for the RNA/DNA extraction, for all patients. We used the Vysis LSI EGFR SpectrumOrange/CEP 7 SpectrumGreen Probe (Abbott Laboratories, Abbott Park, IL, USA), and c-met/CEN7q FISH Probe (Abnova Corp, Taipei, Taiwan) to assess the *EGFR and c-MET (met proto-oncogene)* gene copy number variations. At least 50 cells were assessed for each case by two pathologists and were classified in line with the published criteria, as disomy low polysomy (\<4 copies in \>40% of cells), high polysomy (≥4 copies in \>40% of cells), or gene amplification (homogenously staining regions with ≥ 15 copies in ≥ 10% of cells or a gene/chromosome ratio ≥2:1 per cell).[@b14-ott-7-513],[@b15-ott-7-513]

Immunohistochemistry
--------------------

Corresponding paraffin-embedded tissue sections were analyzed for the protein expression of PIK3CA (1:400 dilution) (PI3 Kinase p110 \[C73F8\] Rabbit mAb \#4249; Cell Signaling Technology, Inc., Danvers, MA, USA) and p-Akt (phosphorylated protein kinase B) (1:50 dilution) (Phospho-Akt \[Ser473\] \[736E11\] Rabbit mAb \#3787; Cell Signaling Technology, Inc.). Immunostaining was evaluated by two blinded observers. Immunoreactivity to any antibody was scored positive if more than 10% cells showed membranous staining of any intensity[@b15-ott-7-513]

Clinical and pathological variables
-----------------------------------

Clinical and pathological data collected for the analyses included sex, age at diagnosis, smoking history, pathological TNM stage, tumor differentiation, and histological type. If a sample was confirmed to be lung adenocarcinoma (immunohistochemistry staining showed thyroid t ranscription factor \[TTF\]-1 and cytokeratin \[CK\]7 positive), the histological subtypes, according to the new International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society (IASLC/ATS/ERS) multidisciplinary classification were collected.[@b16-ott-7-513] Pathological TNM stages were evaluated in accordance with the seventh edition of the lung cancer staging classification system.[@b17-ott-7-513] Patients were interrogated about disease recurrence and survival information, either in clinic or by telephone every 3 months after the date of diagnosis. Relapse-free survival (RFS) was defined as the time elapsed between diagnosis and the date of relapse or last follow-up visit. Overall survival (OS) was calculated from the date of diagnosis to date of death or last follow-up visit.

Statistical analysis
--------------------

We used percentages for qualitative variables, and mean and standard deviation for quantitative variables. Pearson ***X****[@b2-ott-7-513]* test or Fisher's exact tests were used to assess the association between two categorical variables. RFS and OS were compared using the Kaplan--Meier method and logrank test. Cox regression was performed for multivariate analysis of survival. All the statistical analyses were performed using SPSS for Windows (version 16.0) (SPSS Inc., Chicago, IL, USA). *P* values were two tailed for all the tests, and statistical significance was set as *P*\<0.05.

Results
=======

Prevalence of *EGFR* T790M mutation in NSCLC
--------------------------------------------

In all, 1,903 patients were eligible for this analysis, including 1,213 adenocarcinomas, 539 squamous carcinomas, 57 adenosquamous carcinomas, 27 large cell carcinomas, and 67 other NSCLC subtypes. A total of 783 patients were found to harbor *EGFR* mutation, accounting for 41.2% of all the NSCLC cases. Patients harboring *EGFR* T790M accounted for 2.04% of all the *EGFR* mutant cases and 0.84% of the total. There were 14 adenocarcinoma patients who were found to harbor a primary concomitant *EGFR* T790M mutation, accounting for 1.1% of all lung adenocarcinoma cases. Two patients with adenosquamous carcinoma harbored a *EGFR* T790M mutation, accounting for 3.5% of all adenosquamous cases. Ten patients harbored an *EGFR* T790M mutation and L858R mutation concurrently. Five patients harbored *EGFR* T790M mutation and exon 19 in-frame deletions concurrently. One patient harbored *EGFR* T790M, G719S mutations, and *PIK3CA* E542K mutation concurrently. None of the 16 patients had any other oncogenic driver mutations, including *KRAS, HER2, BRAF*, and *EML4-ALK* fusions.

Clinicopathological characteristics of NSCLC patients harboring *EGFR* T790M
----------------------------------------------------------------------------

Primary *EGFR* T790M mutation occurred in 13 females and three males, ranging in age at diagnosis from 45 to 66 (mean age: 59.3) years. Of these, 93.7% (15 of 16) patients had never smoked. Three tumors were poorly differentiated; the other 13 tumors were moderately differentiated. The number of patients in pathological TNM stages I--IV was 8, 2, 5, and 1, respectively. Among the 16 patients, two had adenosquamous carcinomas, and the other 14 had adenocarcinomas. The majority subtype of adenocarcinoma was acinar (n=6), followed by papillary (n=4), micropapillary (n=2), solid and adenocarcinoma in situ. Details of the 16 patients harboring the *EGFR* T790M mutation are listed in [Table 1](#t1-ott-7-513){ref-type="table"}. There were 54 patients with a tumor harboring *EGFR* L858R or exon 19 deletions consecutively enrolled. These samples underwent FISH to detect *EGFR* gene copy number variations. We compared the clinicopathological characteristics between these patients and patients harboring *EGFR* T790M ([Table 2](#t2-ott-7-513){ref-type="table"}).

Clinical outcome
----------------

A total of 94 patients with only *EGFR* L858R mutation and 120 patients with only exon 19 in-frame deletions were consecutively enrolled from May 2009 to October 2012 ([Table S1](#SD1-ott-7-513){ref-type="supplementary-material"}). The follow-up phase of these patients corresponded with that of the 16 patients harboring primary *EGFR* T790M. We analyzed the RFS and OS data of these three subgroups of patients. The median follow-up phase was 28.6 months for all the patients and 20.2 months for patients with *EGFR* T790M mutation. Two patients harboring *EGFR* T790M mutation had received EGFR-TKI treatment: one received gefitinib and had an occurrence of brain metastasis in the sixth month; the other received erlotinib to control the metastasis to the liver. The metastasis in the latter patient was assessed as progressive disease after 2 months of EGFR-TKI treatment. OS was significantly shorter for patients harboring *EGFR* T790M mutation than it was in patients with exon 19 deletions (logrank *P*=0.008). The OS was also shorter in patients with *EGFR* T790M mutation than that in patients harboring an L858R point mutation (logrank *P*=0.09). When taking patients with *EGFR* L858R or exon 19 deletions as one group, the OS was significantly longer than that in patients with T790M mutation (logrank *P*=0.012). There was no significant difference in RFS among three subgroups patients harboring different kinds of *EGFR* mutations (T790M versus exon 19 deletions \[logrank *P*=0.387\]; T790M versus L858R \[logrank *P*=0.951\]) ([Figures 1](#f1-ott-7-513){ref-type="fig"} and [2](#f2-ott-7-513){ref-type="fig"}).

We also performed a multivariate analysis of survival significance of patients harboring a primary *EGFR* T790M mutation. Cox regression showed sex, age at diagnosis, smoking history, tumor differentiation, pathological type, *EGFR* gene copy number variations, and EGFR-TKI therapy had no significant influence on the OS or RFS of these patients.

*EGFR* gene copy number variations, *c-MET* amplification, *PIK3CA*, p-*Akt* expression in NSCLC with *EGFR* T790M mutation
---------------------------------------------------------------------------------------------------------------------------

Among the 16 patients harboring *EGFR* T790M, no *c-MET* amplification was found. Six of the 16 samples (37.5%) were *EGFR*--FISH positive, including two (12.5%) with gene amplification and four (25%) with high polysomy. We compared the frequency of *EGFR* gene copy number variationsm in the 16 patients harboring *EGFR* T790M mutation with that in 54 patients, 28 with *EGFR* exon 19 deletions and 26 with *EGFR* L858R. A lower frequency of FISH-positive cases was found in samples harboring *EGFR* T790M mutation compared with those with exon 19 deletions or L858R ([Table 2](#t2-ott-7-513){ref-type="table"}). Positive *PIK3CA* and p-*Akt* expression were observed in four (25%) and eight (50%) of the 16 patients, respectively ([Figure 3](#f3-ott-7-513){ref-type="fig"}). A total of 108 NSCLC patients without any mutation were consecutively enrolled from May 2009 to October 2012. We compared *PIK3CA* and p-*Akt* expression between these patients and the patients harboring *EGFR* T790M ([Table 3](#t3-ott-7-513){ref-type="table"}).

Discussion
==========

Compared with classic activating *EGFR* mutations, such as L858R and exon 19 in-frame deletions, the clinicopathological and molecular characteristics of NSCLC patients harboring primary T790M mutations remain poorly defined. Somatic *EGFR* T790M is known to occur as a "secondary mutation" in more than 50% of patients in whom acquired resistance to EGFR-TKIs develops.[@b5-ott-7-513],[@b6-ott-7-513] Germline *EGFR* T790M mutation is rare and considered to be associated with genetic susceptibility to lung cancer, and may underlie familial predisposition to the disease.[@b11-ott-7-513] As far as we know, our study represents the largest investigation for the prevalence, clinicopathological features, molecular correlations, and clinical outcome in pretreated East Asian NSCLC patients harboring *EGFR* T790M mutation.

We determined that primary *EGFR* T790M mutation was a rare event in NSCLC patients, and it was mutually exclusive with other well-identified molecular alterations, except for one *PIK3CA* E542K mutation. Prudkin et al[@b18-ott-7-513] identified two (0.83%) cases harboring the *EGFR* T790M mutation from 240 patients with lung adenocarcinomas who had never received treatment with *EGFR* TKIs. Inukai et al[@b19-ott-7-513] found one (0.54%) *EGFR* T790M mutation in 185 NSCLC patients without EGFR-TKI treatment, using mutant-enriched PCR analysis, but the findings could not be confirmed by direct sequencing. Considering the extremely low prevalence of primary *EGFR* T790M mutation in NSCLC patients, screening of this mutation in a large cohort is necessary to define the clinicopathological features and molecular correlations.

Gefitinib-sensitizing *EGFR* mutations, such as L858R and exon 19 in-frame deletions, selectively activate antiapoptosis signaling pathways.[@b20-ott-7-513] Thus, they can enhance the proliferation and the resistance of apoptosis of tumor cell and have been considered to be oncogenic. In our series, primary *EGFR* T790M mutation was found concomitant with either L858R or exon 19 deletions in 15 (93.8%) samples. And no single *EGFR* T790M mutation was found. Also, baseline *EGFR* T790M was proved to be associated with germline molecular alterations.[@b21-ott-7-513] This may indicate that primary T790M mutation alone cannot induce oncogenesis. It can occur before EGFR-TKI treatment because of tumor cell heterogeneity.

A valuable result we found is that patients harboring primary *EGFR* T790M mutation had significantly shorter OS than that did patients harboring *EGFR* exon 19 deletions. And the patients harboring *EGFR* L858R seem to have a longer OS than did the patients with *EGFR* T790M. It was proven that *EGFR* T790M may in fact provide a proliferative advantage by increasing kinase activity and downstream signaling.[@b7-ott-7-513],[@b22-ott-7-513] Our findings indicate that primary *EGFR* T790M mutation might be a predictor for poor prognosis. However, considering the different postoperative treatment strategies these patients received, this finding should be verified. That the RFS was not different among these mutation subtypes may be partly owing to the relatively short follow-up time.

*c-MET* amplification was considered to be a mechanism for acquired resistance to EGFR-TKIs. This molecular change had been found in samples with gefitinib or erlotinib resistance in vivo or in vitro.[@b23-ott-7-513] *c-MET* amplification has also occasionally been found to coexist with *EGFR* T790M mutation.[@b24-ott-7-513] Therefore, we detected this kind of molecular change, using FISH, in the 16 samples harboring *EGFR* T790M, with an attempt to define the association between these two kinds of TKI-resistant-related molecular changes. But we found no *c-MET* amplification in them. This result may indicate that concurrence of the two kinds of molecular change is a rare event in patients who have not undergone EGFR-TKI treatment.

Some former studies using FISH have proposed *EGFR* gene copy number variations as an important predictor of response to EGFR-TKIs.[@b14-ott-7-513],[@b25-ott-7-513],[@b26-ott-7-513] In our study, we found a lower frequency of *EGFR* gene copy number variations in patients harboring *EGFR* T790M than in patients harboring exon 19 deletions and L858R. This result may confirm that primary *EGFR* T790M mutation, as a molecular marker, can induce initial resistance to EGFR-TKIs.

To our knowledge, well-defined EGFR-TKI resistance mechanisms share the same potential concept: they enable the cancer cell to maintain its intracellular growth signaling pathways, especially the phosphatidylinositol 3-kinase (PI3K)--protein kinase B (AKT) pathway.[@b20-ott-7-513],[@b27-ott-7-513]--[@b30-ott-7-513] In our series, we found 50% of samples had an overexpressed level of p-Akt, but a corresponding overexpression were not found in the upstream protein PIK3CA. Our results may indicate primary *EGFR* T790M mutation can induce p-Akt expression through other mechanism, which are yet to be revealed.

In summary, our study of a large cohort described the clinicopathological and molecular characteristics of NSCLC patients harboring primary *EGFR* T790M mutations. Its value of being a predictor for worse prognosis was established. Primary *EGFR* T790M mutation is indeed a rare molecular change in NSCLC cases, but the therapeutic strategies for this subtype of patients should be carefully considered.

Supplementary material
======================

###### 

Details of NSCLC patients harboring *EGFR* L858R mutation or exon 19 deletions

  Sex      Smoking history   Histology        AD subtype       pTNM   *EGFR* mutation type
  -------- ----------------- ---------------- ---------------- ------ ----------------------
  Female   Ever              Adenocarcinoma   Acinar           IA     19 del
  Male     Ever              Adenocarcinoma   Papillary        IIIA   19 del
  Male     Never             Adenocarcinoma   Lepidic          IIIA   19 del
  Female   Never             Adenocarcinoma   Acinar           IIIA   19 del
  Female   Never             Adenocarcinoma   Acinar           IA     19 del
  Male     Ever              Adenocarcinoma   Acinar           IA     19 del
  Male     Ever              Adenocarcinoma   Acinar           IIA    19 del
  Male     Ever              Adenocarcinoma   Papillary        IA     19 del
  Male     Ever              Adenocarcinoma   Lepidic          IA     19 del
  Male     Ever              Adenocarcinoma   Solid            IIA    19 del
  Female   Never             Adenocarcinoma   Solid            IA     19 del
  Female   Never             Adenocarcinoma   Acinar           IB     19 del
  Female   Never             Adenocarcinoma   Acinar           IA     19 del
  Female   Never             Adenocarcinoma   Acinar           IIA    19 del
  Female   Never             Adenocarcinoma   Solid            IIIB   19 del
  Male     Ever              Adenocarcinoma   Papillary        IIIA   19 del
  Female   Never             Adenocarcinoma   Acinar           IIA    19 del
  Female   Never             Adenocarcinoma   Lepidic          IA     19 del
  Female   Never             Adenocarcinoma   Ima              IB     19 del
  Female   Never             Adenocarcinoma   Acinar           IIA    19 del
  Female   Never             Adenocarcinoma   Micropapillary   IA     19 del
  Female   Never             Adenocarcinoma   Solid            IIIA   19 del
  Male     Ever              Adenocarcinoma   Solid            IB     19 del
  Female   Never             Adenocarcinoma   Lepidic          IIIA   19 del
  Male     Never             Adenocarcinoma   Papillary        IA     19 del
  Female   Never             Adenocarcinoma   Acinar           IA     19 del
  Female   Never             Adenocarcinoma   Solid            IIIA   19 del
  Female   Never             Adenocarcinoma   Solid            IIIA   19 del
  Female   Never             Adenocarcinoma   Papillary        IIIB   19 del
  Female   Ever              Adenocarcinoma   Acinar           IIA    19 del
  Female   Never             Adenocarcinoma   Solid            IB     19 del
  Male     Never             Adenocarcinoma   Papillary        IA     19 del
  Female   Never             Adenocarcinoma   Acinar           IA     19 del
  Female   Never             Adenocarcinoma   Acinar           IIIA   19 del
  Female   Never             Adenocarcinoma   Acinar           IA     19 del
  Female   Never             Adenocarcinoma   Papillary        IB     19 del
  Female   Never             Adenocarcinoma   Papillary        IB     19 del
  Female   Never             Adenocarcinoma   Acinar           IA     19 del
  Female   Never             Adenocarcinoma   Lepidic          IB     19 del
  Male     Ever              Adenocarcinoma   Papillary        IIIA   19 del
  Female   Never             Adenocarcinoma   Acinar           IA     19 del
  Female   Never             Adenocarcinoma   Papillary        IIIA   19 del
  Male     Ever              Adenocarcinoma   Acinar           IB     19 del
  Female   Never             Adenocarcinoma   Solid            IB     19 del
  Male     Never             Adenocarcinoma   Acinar           IA     19 del
  Female   Never             Adenocarcinoma   Acinar           IB     19 del
  Female   Never             Adenocarcinoma   Acinar           IIIA   19 del
  Male     Never             Adenocarcinoma   Papillary        IIA    19 del
  Female   Never             Adenocarcinoma   Solid            IIA    19 del
  Female   Never             Adenocarcinoma   Acinar           IB     19 del
  Female   Never             Adenocarcinoma   Acinar           IA     19 del
  Male     Ever              Adenocarcinoma   Acinar           IIIA   19 del
  Female   Never             Adenocarcinoma   Acinar           IB     19 del
  Male     Never             Adenocarcinoma   Acinar           IB     19 del
  Male     Never             Adenocarcinoma   Papillary        IIIA   19 del
  Male     Never             Adenocarcinoma   Acinar           IIIA   19 del
  Female   Never             Adenocarcinoma   Ima              IB     19 del
  Female   Never             Adenocarcinoma   Acinar           IIA    19 del
  Male     Ever              Adenocarcinoma   Acinar           IV     19 del
  Female   Never             Adenocarcinoma   Lepidic          IA     19 del
  Female   Never             Adenocarcinoma   Papillary        IIIA   19 del
  Male     Ever              Adenocarcinoma   Acinar           IA     19 del
  Female   Never             Adenocarcinoma   Lepidic          IB     19 del
  Male     Never             Adenocarcinoma   Acinar           IB     19 del
  Male     Ever              Adenocarcinoma   Acinar           IIIA   19 del
  Female   Never             Adenocarcinoma   Acinar           IIIA   19 del
  Male     Ever              Adenocarcinoma   Papillary        IA     19 del
  Male     Ever              Adenocarcinoma   Acinar           IIIA   19 del
  Female   Never             Adenocarcinoma   Acinar           IB     19 del
  Female   Never             Adenocarcinoma   Papillary        IB     19 del
  Female   Never             Adenocarcinoma   Acinar           IA     19 del
  Female   Never             Adenocarcinoma   Acinar           IIIA   19 del
  Female   Never             Adenocarcinoma   Solid            IIIA   19 del
  Female   Never             Adenocarcinoma   Acinar           IA     19 del
  Male     Ever              Adenocarcinoma   Acinar           IB     19 del
  Male     Ever              Adenocarcinoma   Acinar           IIIA   19 del
  Female   Never             Adenocarcinoma   Acinar           IIIA   19 del
  Female   Never             Adenocarcinoma   Acinar           IA     19 del
  Female   Never             Adenocarcinoma   Papillary        IB     19 del
  Female   Never             Adenocarcinoma   Acinar           IIIA   19 del
  Male     Ever              Adenocarcinoma   Acinar           IIIA   19 del
  Female   Never             Adenocarcinoma   Acinar           IB     19 del
  Male     Ever              Adenocarcinoma   Solid            IIA    19 del
  Male     Ever              Adenocarcinoma   Papillary        IIA    19 del
  Male     Ever              Adenocarcinoma   Solid            IA     19 del
  Male     Ever              Adenocarcinoma   Acinar           IB     19 del
  Male     Never             Adenocarcinoma   Acinar           IIA    19 del
  Female   Never             Adenocarcinoma   Acinar           IB     19 del
  Female   Never             Adenocarcinoma   Lepidic          IB     19 del
  Female   Never             Adenocarcinoma   Papillary        IIIA   19 del
  Female   Never             Adenocarcinoma   Papillary        IIIA   19 del
  Female   Never             Adenocarcinoma   Solid            IIA    19 del
  Male     Ever              Adenocarcinoma   Acinar           IIIA   19 del
  Female   Never             Adenocarcinoma   Solid            IIIA   19 del
  Female   Never             Adenocarcinoma   MIA              IA     19 del
  Female   Never             Adenocarcinoma   Acinar           IA     19 del
  Female   Never             Adenocarcinoma   Micropapillary   IIA    19 del
  Female   Never             Adenocarcinoma   Acinar           IB     19 del
  Female   Never             Adenocarcinoma   Acinar           IIIA   19 del
  Male     Ever              Adenocarcinoma   Papillary        IB     19 del
  Female   Never             Adenocarcinoma   Acinar           IB     19 del
  Male     Ever              Adenocarcinoma   Acinar           IIIA   19 del
  Female   Never             Adenocarcinoma   Lepidic          IA     19 del
  Female   Never             Adenocarcinoma   Solid            IIIA   19 del
  Male     Ever              Adenocarcinoma   Acinar           IIIA   19 del
  Female   Never             Adenocarcinoma   Acinar           IA     19 del
  Female   Never             Adenocarcinoma   Acinar           IA     19 del
  Female   Never             Adenocarcinoma   Lepidic          IA     19 del
  Female   Never             Adenocarcinoma   Acinar           IB     19 del
  Female   Never             Adenocarcinoma   Lepidic          IA     19 del
  Female   Never             Adenocarcinoma   Acinar           IB     19 del
  Female   Never             Adenocarcinoma   Lepidic          IA     19 del
  Female   Never             Adenocarcinoma   Acinar           IB     19 del
  Male     Ever              Adenocarcinoma   Papillary        IIIA   19 del
  Female   Never             Adenocarcinoma   Acinar           IA     19 del
  Male     Never             Adenocarcinoma   Micropapillary   IIIA   19 del
  Female   Never             Adenocarcinoma   Acinar           IA     19 del
  Female   Never             Adenocarcinoma   AIS              IA     19 del
  Female   Never             Adenocarcinoma   Acinar           IIIA   19 del
  Male     Ever              Adenocarcinoma   Papillary        IB     19 del
  Male     Ever              Adenocarcinoma   Acinar           IA     L858R
  Female   Never             Adenocarcinoma   Acinar           IIIA   L858R
  Male     Ever              Adenocarcinoma   Papillary        IA     L858R
  Male     Never             Adenocarcinoma   Papillary        IIIA   L858R
  Male     Ever              Adenocarcinoma   Solid            IIIA   L858R
  Female   Never             Adenocarcinoma   AIS              IA     L858R
  Female   Never             Adenocarcinoma   Papillary        IB     L858R
  Female   Never             Adenocarcinoma   Acinar           IIIA   L858R
  Female   Never             Adenocarcinoma   Papillary        IA     L858R
  Male     Ever              Adenocarcinoma   Papillary        IA     L858R
  Female   Never             Adenocarcinoma   Acinar           IIIA   L858R
  Female   Never             Adenocarcinoma   Acinar           IB     L858R
  Female   Never             Adenocarcinoma   Papillary        IA     L858R
  Female   Never             Adenocarcinoma   Solid            IIA    L858R
  Male     Never             Adenocarcinoma   Papillary        IIB    L858R
  Female   Never             Adenocarcinoma   Acinar           IA     L858R
  Female   Never             Adenocarcinoma   Papillary        IIA    L858R
  Female   Never             Adenocarcinoma   Papillary        IIIA   L858R
  Female   Never             Adenocarcinoma   Acinar           IA     L858R
  Male     Ever              Adenocarcinoma   Acinar           IIA    L858R
  Female   Never             Adenocarcinoma   Acinar           IIIA   L858R
  Female   Never             Adenocarcinoma   Acinar           IA     L858R
  Female   Never             Adenocarcinoma   Acinar           IIIA   L858R
  Male     Ever              Adenocarcinoma   Solid            IIIA   L858R
  Male     Ever              Adenocarcinoma   Lepidic          IA     L858R
  Male     Ever              Adenocarcinoma   Acinar           IIIA   L858R
  Male     Never             Adenocarcinoma   Acinar           IA     L858R
  Male     Never             Adenocarcinoma   Acinar           IA     L858R
  Female   Never             Adenocarcinoma   MIA              IA     L858R
  Female   Never             Adenocarcinoma   Acinar           IB     L858R
  Female   Never             Adenocarcinoma   Acinar           IB     L858R
  Female   Never             Adenocarcinoma   Acinar           IA     L858R
  Female   Never             Adenocarcinoma   Acinar           IA     L858R
  Female   Never             Adenocarcinoma   Acinar           IA     L858R
  Female   Never             Adenocarcinoma   Acinar           IIIB   L858R
  Female   Never             Adenocarcinoma   Lepidic          IA     L858R
  Male     Never             Adenocarcinoma   Micropapillary   IIIA   L858R
  Female   Never             Adenocarcinoma   Papillary        IIIA   L858R
  Male     Ever              Adenocarcinoma   Acinar           IIIA   L858R
  Male     Never             Adenocarcinoma   Acinar           IB     L858R
  Female   Never             Adenocarcinoma   Lepidic          IB     L858R
  Female   Never             Adenocarcinoma   Acinar           IB     L858R
  Female   Never             Adenocarcinoma   Ima              IIIA   L858R
  Male     Ever              Adenocarcinoma   Acinar           IIIA   L858R
  Female   Never             Adenocarcinoma   Acinar           IIIA   L858R
  Male     Ever              Adenocarcinoma   Papillary        IIIA   L858R
  Male     Never             Adenocarcinoma   Lepidic          IB     L858R
  Male     Ever              Adenocarcinoma   Solid            IA     L858R
  Male     Ever              Adenocarcinoma   Solid            IV     L858R
  Female   Never             Adenocarcinoma   Acinar           IA     L858R
  Female   Never             Adenocarcinoma   Acinar           IB     L858R
  Female   Never             Adenocarcinoma   Acinar           IIIA   L858R
  Female   Never             Adenocarcinoma   Papillary        IA     L858R
  Male     Never             Adenocarcinoma   Acinar           IA     L858R
  Male     Ever              Adenocarcinoma   Papillary        IIA    L858R
  Female   Never             Adenocarcinoma   Acinar           IB     L858R
  Female   Never             Adenocarcinoma   Acinar           IA     L858R
  Female   Never             Adenocarcinoma   Acinar           IA     L858R
  Female   Never             Adenocarcinoma   Micropapillary   IA     L858R
  Female   Never             Adenocarcinoma   Papillary        IIIA   L858R
  Female   Never             Adenocarcinoma   Acinar           IIIA   L858R
  Female   Never             Adenocarcinoma   Acinar           IA     L858R
  Female   Never             Adenocarcinoma   Acinar           IB     L858R
  Female   Never             Adenocarcinoma   Solid            IIIA   L858R
  Female   Never             Adenocarcinoma   Acinar           IIIA   L858R
  Male     Ever              Adenocarcinoma   Acinar           IIIA   L858R
  Female   Never             Adenocarcinoma   Acinar           IA     L858R
  Female   Never             Adenocarcinoma   Lepidic          IA     L858R
  Male     Never             Adenocarcinoma   MIA              IA     L858R
  Female   Never             Adenocarcinoma   Acinar           IB     L858R
  Female   Never             Adenocarcinoma   Acinar           IA     L858R
  Male     Ever              Adenocarcinoma   Acinar           IA     L858R
  Male     Ever              Adenocarcinoma   Papillary        IIIA   L858R
  Female   Never             Adenocarcinoma   Acinar           IB     L858R
  Male     Never             Adenocarcinoma   Acinar           IIA    L858R
  Female   Never             Adenocarcinoma   Acinar           IB     L858R
  Female   Never             Adenocarcinoma   Solid            IIIA   L858R
  Female   Never             Adenocarcinoma   Acinar           IB     L858R
  Female   Never             Adenocarcinoma   Papillary        IA     L858R
  Male     Never             Adenocarcinoma   Papillary        IB     L858R
  Female   Never             Adenocarcinoma   Acinar           IB     L858R
  Female   Never             Adenocarcinoma   Acinar           IA     L858R
  Female   Never             Adenocarcinoma   Lepidic          IA     L858R
  Female   Never             Adenocarcinoma   Acinar           IIA    L858R
  Female   Never             Adenocarcinoma   Acinar           IA     L858R
  Female   Never             Adenocarcinoma   Lepidic          IB     L858R
  Male     Ever              Adenocarcinoma   Solid            IIB    L858R
  Female   Never             Adenocarcinoma   Acinar           IA     L858R
  Female   Never             Adenocarcinoma   Acinar           IIIA   L858R
  Female   Never             Adenocarcinoma   Lepidic          IA     L858R
  Female   Never             Adenocarcinoma   Papillary        IA     L858R
  Female   Never             Adenocarcinoma   Papillary        IIA    L858R
  Male     Ever              Adenocarcinoma   Acinar           IIB    L858R
  Female   Never             Adenocarcinoma   Solid            IIIA   L858R

**Abbreviations:** AD, adenocarcinoma; AIS, adenocarcinoma in situ; del, deletion; *EGFR, epidermal growth factor receptor*; Ima, invasive mucinous adenocarcinoma; pTNM, pathological TNM stage; NSCLC, non-small cell lung cancer; MIA, minimally invasive adenocarcinoma.
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###### 

Clinicopathological and molecular characteristics of 16 patients harboring primary *EGFR* T790M mutation

  No   Sex   Age   Smoking history   Histology   AD subtype   Diff       pTNM   *EGFR* mutation type   *EGFR* copy number   Other driver mutation   Treatment
  ---- ----- ----- ----------------- ----------- ------------ ---------- ------ ---------------------- -------------------- ----------------------- -------------------------
  1    F     53    Never             AD          Acinar       Moderate   Ia     Del E746-A750, T790M   Amplification        --                      --
  2    F     66    Never             AD          MP           Moderate   IV     L858R, T790M           --                   --                      Gefitinib
  3    F     62    Never             AD          Acinar       Moderate   Ib     L858R, T790M           --                   --                      --
  4    F     66    Never             AD          P            Moderate   IIb    Del E746-A750, T790M   --                   --                      Erlotinib
  5    F     64    Never             AD          Acinar       Moderate   IIa    L858R, T790M           --                   --                      --
  6    M     45    Never             AS          --           Poor       Ib     L858R, T790M           High polysomy        --                      --
  7    M     62    Smoker            AD          Acinar       Moderate   IIIb   L858R, T790M           Amplification        --                      Gemcitabine + cisplatin
  8    F     62    Never             AS          --           Poor       IIIa   Del l747-T751, T790M   High polysomy        --                      Gemcitabine + cisplatin
  9    F     65    Never             AD          Acinar       Moderate   Ib     L858R, T790M           --                   --                      --
  10   F     66    Never             AD          Solid        Poor       IIIa   G719S, T790M           High polysomy        *PIK3CA* E542K          Gemcitabine + cisplatin
  11   F     54    Never             AD          Acinar       Moderate   IIIa   L858R, T790M           High polysomy        --                      Paclitaxel + cisplatin
  12   F     57    Never             AD          MP           Moderate   Ia     Del L747-T751, T790M   --                   --                      --
  13   M     57    Never             AD          P            Moderate   Ia     Del l747-T751, T790M   --                   --                      --
  14   F     58    Never             AD          P            Moderate   Ia     L858R, T790M           --                   --                      --
  15   F     58    Never             AD          AIS          Moderate   Ia     L858R, T790M           --                   --                      --
  16   F     53    Never             AD          P            Moderate   IIIa   L858R, T790M           --                   --                      Gemcitabine + cisplatin

**Abbreviations:** AD, adenocarcinoma; AIS, adenocarcinoma in situ; AS, adenosquamous carcinoma; Diff, differentiation; *EGFR, epidermal growth factor receptor*; F, female; M, male; MP, micropapillary predominant; P, papillary predominant; *PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha*; pTNM, pathological TNM stage.

###### 

Comparison of clinicopathological and molecular characteristics between NSCLC patients harboring *EGFR* T790M mutations and those with classic activating mutations

  ----------------------------------------------------------------------------------------------------------------------------------------------------
  Variables             T790M\   Exon 19 del\   *P*[a](#tfn2-ott-7-513){ref-type="table-fn"}   L858R\   *P*[b](#tfn3-ott-7-513){ref-type="table-fn"}
                        (n=16)   (n=28)                                                        (n=26)   
  --------------------- -------- -------------- ---------------------------------------------- -------- ----------------------------------------------
  Age (years)                                                                                           

   Mean                 59.3     58.5                                                          61.9     

   SD                   6        10.2           0.734                                          6.8      0.452

  Sex                                                                                                   

   Female               13       17                                                            14       

   Male                 3        11             0.195                                          12       0.102

  Smoking history                                                                                       

   Ever                 1        9                                                             8        

   Never                15       19             0.067                                          18       0.119

  Differentiation                                                                                       

   Poor                 3        5                                                             9        

   Moderate/Well        13       23             1                                              17       0.316

  Stage                                                                                                 

   I                    8        10                                                            9        

   II                   2        7                                                             5        

   III                  5        10                                                            12       

   IV                   1        1              0.681                                          0        0.389

  Histologic subtypes                                                                                   

   AIS                  1        0              --                                             2        1

   MIA                  0        1              --                                             1        --

   Lepidic              0        4              --                                             1        --

   Papillary            4        6              0.707                                          10       0.730

   Acinar               6        13             0.826                                          7        0.305

   Solid                1        4              0.650                                          5        0.399

   Micropapillary       2        0              --                                             0        --

  *EGFR* FISH                                                                                           

   Positive             6        14                                                            17       

   Negative             10       14             0.423                                          9        0.078
  ----------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Comparison between T790M and exon 19 deletions;

comparison between T790M and L858R.

**Abbreviations:** AIS, adenocarcinoma in situ; *EGFR, epidermal growth factor receptor*; FISH, fluorescence in situ hybridization; MIA, minimally invasive adenocarcinoma; NSCLC, non-small cell lung cancer; SD, standard deviation.

###### 

Comparison of *PIK3CA*, p-*Akt* expression between patients harboring *EGFR* T790M mutation and those without any mutation

                                                   *PIK3CA*   p-*Akt*                     
  ------------------------------------------------ ---------- --------- ------- ---- ---- -------
  *EGFR* T790M                                     41         67        0.409   33   75   0.156
  NSCLC[a](#tfn5-ott-7-513){ref-type="table-fn"}   4          12                8    8    

**Note:**

Non-small cell lung cancer patients harboring no mutation.

**Abbreviations:** *EGFR, epidermal growth factor receptor*; NSCLC, non-small cell lung cancer; p-*Akt*, phosphorylated *protein kinase B; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha*.
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